Key result
Catheter-directed urokinase and intraprocedural alteplase show comparable efficacy and safety for intermediate-risk PE.
Why the study?
The clinical efficacy and safety of anticoagulation combined with catheter-directed urokinase thrombolysis versus catheter-directed alteplase infusion thrombolysis in intermediate-risk acute pulmonary embolism had not been compared directly.
Does intraprocedural alteplase infusion improve clinical efficacy and safety compared to continuous urokinase infusion in patients with intermediate-risk acute pulmonary embolism?
Does intraprocedural alteplase infusion improve clinical efficacy and safety compared to continuous urokinase infusion in patients with intermediate-risk acute pulmonary embolism?
Answers are grounded in this paper and cite their sources.
Should not yet change practice; hypothesis-generating for randomized trials in intermediate-risk pulmonary embolism.
Objective To compare the clinical efficacy and safety of anticoagulation combined with catheter-directed urokinase (UK) thrombolysis vs. anticoagulation combined with catheter-directed alteplase (rt-PA) infusion thrombolysis in patients with intermediate-risk acute pulmonary embolism (APE). Methods A retrospective analysis was conducted on intermediate-risk APE patients treated at our center between June 2022 and May 2025, all of whom received anticoagulation combined with catheter-directed thrombolysis. The UK group ( n = 56) received continuous UK infusion via pulmonary artery catheter (400,000–500,000 IU/day for 2–3 days), while the rt-PA group ( n = 23) received intraprocedural rt-PA infusion (20 mg/30 min). Changes in cardiac troponin I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), right ventricular diameter/left ventricular diameter (RVD/LVD), and pulmonary artery obstruction index (PAOI) were compared before and after treatment. Results Baseline characteristics showed no significant differences between groups ( P > 0.05). Post-treatment, the UK group demonstrated significant improvements in PAOI, RVD/LVD, NT-proBNP, and cTnI ( P < 0.05), while the rt-PA group showed significant improvements in PAOI, RVD/LVD, and cTnI ( P < 0.05) but not NT-proBNP ( P = 0.088). There were no statistically significant differences in the aforementioned indicators between the two groups at both pre-treatment and post-treatment time points ( P > 0.05). There were no statistically significant differences in in-hospital mortality, the incidence of bleeding adverse events, and hospital stay duration between the two groups ( P > 0.05). Conclusion For intermediate-risk APE, catheter-directed UK thrombolysis and intraprocedural rt-PA infusion offer comparable efficacy and safety. However, the rt-PA regimen may be more advantageous due to its avoidance of prolonged catheter placement.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question. Catheter-directed urokinase and intraprocedural alteplase showed comparable efficacy and safety in treating intermediate-risk pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: